Case Report: Effect of setmelanotide treatment in a young patient with acquired hypothalamic obesity following Escherichia coli sepsis and meningoencephalitis with brain abscess - Report - MDSpire
Advertisement
Case Report: Effect of setmelanotide treatment in a young patient with acquired hypothalamic obesity following Escherichia coli sepsis and meningoencephalitis with brain abscess
Clinical Report: Impact of Setmelanotide on Acquired Hypothalamic Obesity
Overview
This case study details the effects of setmelanotide on a 22-month-old child with acquired hypothalamic obesity following Escherichia coli sepsis. Over 13 months, treatment led to weight stabilization, improved liver enzymes, and enhanced quality of life, suggesting setmelanotide's potential as a therapeutic option in similar cases.
Background
Acquired hypothalamic obesity (aHO) is a rare condition resulting from hypothalamic injury, leading to severe obesity and metabolic complications. Current treatment options are limited, making the exploration of new therapies critical. Setmelanotide, a melanocortin-4 receptor agonist, has shown promise in addressing the underlying mechanisms of aHO, potentially improving patient outcomes.
Data Highlights
Parameter
Before Treatment
After Treatment
Body Weight
Increased
Stabilized/Reduced
Liver Enzymes
Elevated
Improved
Lipid Profile
Abnormal
Improved
Motor Activity
Decreased
Increased
Key Findings
Setmelanotide was administered at doses starting from 0.25 mg daily, titrated to 1.5 mg.
Significant clinical improvements were observed at doses ≥1.25 mg daily.
The patient experienced stabilization and reduction in body weight over 13 months.
Improvements in liver enzymes and lipid profile were noted during treatment.
Enhanced motor activity and quality of life were reported by caregivers.
Clinical Implications
The findings suggest that setmelanotide may be a viable treatment option for young patients with acquired hypothalamic obesity, particularly those with inflammation-related causes. Clinicians should consider this therapy in the context of a multidisciplinary approach to manage associated metabolic complications.
Conclusion
Setmelanotide shows promise as a therapeutic strategy for acquired hypothalamic obesity, with significant improvements in weight management and quality of life. Further studies are warranted to establish its efficacy across broader patient populations.
